Stem Cell Transplant or Cellular Therapy - Allogeneic

- **MDS Only**
  - **IRB 10146**
    - Compares reduced intensity allogeneic stem cell transplant to hypomethylating therapy or best supportive care in patients aged 50-75 with intermediate - 2 and high risk myelodysplastic syndrome.

- **AML Only**
  - **IRB 17622**
    - Tests the drug Gilteritinib with a placebo for AML with a FLT3/ITD mutation after allogeneic transplant.

- **AML/MDS Only**
  - **IRB 16995**
    - Tests the drug PRO 140 compared to placebo to prevent Graft vs. Host Disease in AML and MDS patients undergoing allogeneic stem cell transplants.
  - **IRB 16189**
    - Phase 1/phase 2 study of ProTmune ex vivo mobilized peripheral blood cells.
  - **IRB 18142**
    - Safety and Efficacy study of ATIR101 Compared to Post-transplant Cyclophosphamide for the prevention of GVHD in a haploidentical transplant (HATCY).

- **AML/MDS/ALL**
  - **IRB 16943**
    - BMT CTN phase II study of ATG-based conditioning regimens for haploidentical and cord blood transplants.

- **Severe Aplastic Anemia**
  - **IRB 16943**
    - Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients.

- **Multiple Diseases**
  - **IRB 18301**
    - Tests the drug PRO 140 compared to placebo to prevent Graft vs. Host Disease in AML and MDS patients undergoing allogeneic stem cell transplants.
  - **IRB 18301**
    - Donor T-Cell infusion for adults with recurrent minimal residual disease post HSCT.
  - **IRB 9375**
    - Phase 1-2 BPX-501 T Cells after Partially Mismatched, Related Donor T Cell-Depleted Stem Cell Transplant.

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

8/30/2018